A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
This study is testing a new type of cell-based treatment called MT-401-OTS for patients with specific blood cancers, including AML and MDS. The goal is to see if these pre-made immune cells can help fight cancer that has returned after previous treatments.
This trial is for adults aged 65 and older who have been diagnosed with certain types of AML or MDS. Participants must be mobile, generally active, and have a partial genetic match for the treatment product.
Participants will receive the experimental MT-401-OTS therapy, which uses specially prepared immune cells to target the cancer. Doctors will carefully monitor your safety and response to the treatment throughout the study period.
The study is currently recruiting patients at medical centers in Duarte, California; Tampa, Florida; and Kansas City, Kansas. Please check with your doctor to see if one of these locations is an option for you.
- 1This is an early-stage study testing the safety of a new, 'off-the-shelf' immune cell therapy.
- 2The treatment is designed for patients who have not fully responded to their previous blood cancer treatments.
- 3A genetic compatibility check is required to ensure you can receive the specific therapy product.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.